



Universiteit
Leiden
The Netherlands

Thyroid dysfunction and anaemia in a large population-based study

M'Rabet-Bensalah, K.; Aubert, C.E.; Coslovsky, M.; Collet, T.H.; Baumgartner, C.; Elzen, W.P.J. den; ... ; Rodondi, N.

Citation

M'Rabet-Bensalah, K., Aubert, C. E., Coslovsky, M., Collet, T. H., Baumgartner, C., Elzen, W. P. J. den, ... Rodondi, N. (2016). Thyroid dysfunction and anaemia in a large population-based study. *Clinical Endocrinology*, 84(4), 627-631. doi:10.1111/cen.12994

Version: Publisher's Version

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/4284072>

Note: To cite this publication please use the final published version (if applicable).

**RAPID
COMMUNICATION**

Thyroid dysfunction and anaemia in a large population-based study

Khadija M'Rabet-Bensalah^{*1}, Carole E. Aubert^{*1}, Michael Coslovsky[†], Tinh-Hai Collet^{‡§}, Christine Baumgartner^{*}, Wendy P. J. den Elzen[¶], Robert Luben^{**}, Anne Angelillo-Scherrer^{††}, Drahomir Aujesky^{*}, Kay-Tee Khaw^{**} and Nicolas Rodondi^{*}

^{*}Department of General Internal Medicine, Inselspital, University Hospital of Bern, Bern, [†]Department of Clinical Research, Clinical Trial Unit (CTU), University of Bern, Bern, [‡]Service of Endocrinology, Diabetes and Metabolism, University Hospital of Lausanne, Lausanne, Switzerland, [§]University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK, [¶]Department of Public Health and Primary Care and Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands, ^{**}Department of Public Health and Primary Care, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK and ^{††}University Clinic of Hematology and Central Hematology Laboratory, Inselspital, University Hospital of Bern, Bern, Switzerland

Summary

Objective and background Anaemia and thyroid dysfunction are common and often co-occur. Current guidelines recommend the assessment of thyroid function in the work-up of anaemia, although evidence on this association is scarce.

Patients and methods In the 'European Prospective Investigation of Cancer' (EPIC)-Norfolk population-based cohort, we aimed to examine the prevalence and type of anaemia (defined as haemoglobin <13 g/dl for men and <12 g/dl for women) according to different thyroid function groups.

Results The mean age of the 8791 participants was 59.4 (SD 9.1) years and 55.2% were women. Thyroid dysfunction was present in 437 (5.0%) and anaemia in 517 (5.9%) participants. After excluding 121 participants with three most common causes of anaemia (chronic kidney disease, inflammation, iron deficiency), anaemia was found in 4.7% of euthyroid participants. Compared with the euthyroid group, the prevalence of anaemia was significantly higher in overt hyperthyroidism (14.6%, $P < 0.01$), higher with borderline significance in overt hypothyroidism (7.7%, $P = 0.05$) and not increased in subclinical thyroid dysfunction (5.0% in subclinical hypothyroidism, 3.3% in subclinical hyperthyroidism). Anaemia associated with thyroid dysfunction was mainly normocytic (94.0%), and rarely macrocytic (6.0%).

Conclusion The prevalence of anaemia was higher in overt hyperthyroidism, but not increased in subclinical thyroid dysfunction. Systematic measurement of thyroid-stimulating hormone in anaemic patients is likely to be useful only after excluding common causes of anaemia.

(Received 26 August 2015; returned for revision 12 October 2015; finally revised 4 November 2015; accepted 1 December 2015)

Introduction

Anaemia and thyroid dysfunction are common disorders that often co-occur in the elderly.^{1,2} More than 10% of patients aged ≥ 65 years have anaemia³ and the prevalence of subclinical thyroid dysfunction increases with age, with 15–20% of those above 60 years having subclinical hypothyroidism.^{4,5} Hypothyroidism may lead to anaemia because of bone marrow repression and decrease in erythropoietin secretion,⁶ while the relationship between hyperthyroidism and anaemia is less clear.^{7–10} In a recent study, the prevalence of hypothyroidism in 316 hospitalized patients above 65 years was significantly higher in the presence of anaemia (31 of 155 patients) compared to their counterparts without anaemia (16 of 161; $P = 0.01$);¹ however, this study was limited by its small size, by the hospital setting and did not differentiate between overt and subclinical hypothyroidism.

Furthermore, the relationship between thyroid dysfunction and the type of anaemia (micro-, normo- or macrocytic) remains unclear. Hypothyroidism has been associated with macrocytosis, and even though this association seems uncommon and particularly related to severe hypothyroidism, TSH measurement is commonly recommended in the work-up of macrocytosis.^{11–14} Other studies showed that anaemia due to

Correspondence: Nicolas Rodondi, Department of General Internal Medicine, Inselspital, University Hospital of Bern, 3010 Bern, Switzerland. Tel.: +41 (0)31 632 41 63; Fax: +41 (0)31 632 88 85; E-mail: nicolas.rodondi@insel.ch

¹K.M.B. and C.E.A. contributed equally to the preparation of the manuscript. This work was done in the Department of General Internal Medicine, Inselspital, University Hospital of Bern, 3010 Bern, Switzerland.

thyroid dysfunction is more often normocytic than macrocytic.^{6,15–17} Even though data on the association between thyroid dysfunction and anaemia remain scarce, TSH measurement is still recommended in the initial work-up of anaemia.^{2,11–14}

To fill this gap in knowledge, we examined the prevalence of anaemia according to different thyroid function groups and assessed the type of anaemia associated with thyroid dysfunction in a large population-based study.

Methods

Patients and laboratory data

After excluding participants with central thyroid dysfunction (normal TSH and abnormal free T4 [fT4] or concomitant high/low TSH and fT4, $N = 331$), we examined 8791 men and women aged 39–79 years with measured thyroid function (TSH and fT4) and haematological parameters at baseline in the population-based 'European Prospective Investigation of Cancer' (EPIC)-Norfolk study previously detailed elsewhere.¹⁸ The study was approved by the Norwich local research ethics committee, UK, and written informed consent was provided by all participants.

Thyroid dysfunction was defined as hypothyroidism when TSH was >4.49 mIU/L, either subclinical (SHypo) with normal fT4 or overt (OHypo) with low fT4, and as hyperthyroidism when TSH was <0.45 mIU/L, either subclinical (SHyper) with normal fT4 or overt (OHyper) with elevated fT4. Following the WHO definition,¹⁹ anaemia was defined as haemoglobin (Hb) <13 g/dl for men and <12 g/dl for women, and further classified into microcytic anaemia with mean corpuscular volume (MCV) <80 fl, normocytic with MCV 80–100 fl and macrocytic with MCV >100 fl. Ferritin, C-reactive protein (CRP) and creatinine were measured at baseline to assess three most common causes of anaemia.^{20,21} For this purpose, iron deficiency was defined as ferritin <15 ng/ml,²² inflammatory disease as CRP ≥ 10 mg/l²³ and chronic kidney disease as estimated glomerular filtration rate (eGFR) ≤ 30 ml/min/1.73 m², using the MDRD equation,^{24,25} while less conservative cut-offs were used in sensitivity analyses.^{22,26} In the EPIC-Norfolk study, 8791 adults had TSH, ferritin, CRP and eGFR measurements and were available for this analysis.

Statistical analyses

We studied the prevalence of anaemia in the overall sample and in five groups defined according to their thyroid status (euthyroid, OHypo, SHypo, SHyper, OHyper). We compared the prevalence of anaemia between these groups using Fisher's exact tests of association. We compared Hb concentration across the groups using age- and sex-adjusted quadratic pattern linear regression with robust standard errors.

Results and discussion

Among the 8791 participants, the mean age was 59.4 (SD 9.1) years and 55.2% were women. Thyroid dysfunction was present in 917 (10.4%) participants and anaemia in 517 (5.9%).

Among the anaemic participants, 56 (10.8%) had iron deficiency, 58 (11.2%) an inflammatory state, 6 (1.2%) chronic kidney disease and 1 (0.2%) an inflammatory state and chronic kidney disease. After excluding participants with these three most common causes of anaemia, the prevalence of thyroid dysfunction (abnormal TSH) was 12.6% (50 of 396 participants). The prevalence of anaemia was 4.5% among participants with euthyroidism compared to 7.7% in participants with OHypo ($P = 0.05$), 5.0% in those with SHypo ($P = 0.57$), 3.3% in those with SHyper ($P = 0.50$) and 14.6% in those with OHyper ($P < 0.01$, Table 1). Only 4.8% (19/396) of these anaemic participants had overt thyroid dysfunction. In a sensitivity analysis using less conservative cut-offs, 289 of the 517 anaemic participants had chronic kidney disease with eGFR <60 ml/min/1.73 m²,²⁶ iron deficiency with ferritin <30 ng/ml²² and/or inflammatory disease. After excluding them, the proportion of 4.8% with anaemia and overt thyroid dysfunction dropped to 3.1% (7/228, data not shown). In another sensitivity analysis with lower Hb cut-offs (<12 g/dl for men and <11 g/dl for women), the prevalence of anaemia was 3.0% (263 of 8699) and remained significantly higher in participants with OHyper only, compared to euthyroidism (10.4% vs 2.9%, $P < 0.01$). Anaemia was normocytic in 94.0% and macrocytic in 6.0% of the participants with thyroid dysfunction, but never microcytic (Table 2).

In age- and sex-adjusted analyses, Hb concentration was lower in participants with both hyper- or hypothyroid dysfunction compared to the euthyroid state (P -value for quadratic pattern < 0.001). The only group which significantly differed from the euthyroid reference was OHyper (Hb -0.49 g/dl; CI -0.93 to -0.05 ; $P = 0.03$), while the difference was borderline significant for OHypo (Hb -0.17 g/dl; CI -0.33 to 0.00 ; $P = 0.05$; Fig. 1).

Table 1. Prevalence of anaemia within the different thyroid function groups after excluding the participants with three most common causes of anaemia*

Thyroid function group	Total $n = 8670$	Anaemia $n = 396$ (4.5%)	P -value†
Overt hypothyroidism	143	12 (7.7)	0.05
Subclinical hypothyroidism	461	24 (5.0)	0.57
Euthyroidism (reference)	7424	346 (4.5)	–
Subclinical hyperthyroidism	205	7 (3.3)	0.50
Overt hyperthyroidism	41	7 (14.6)	<0.01

*121 participants were excluded as they had iron deficiency (defined as ferritin <15 ng/ml, $n = 56$), inflammatory state (CRP ≥ 10 mg/l, $n = 58$), chronic kidney disease (estimated glomerular filtration rate ≤ 30 ml/min/1.73 m², $n = 6$), or both inflammatory state and chronic kidney disease ($n = 1$). In a sensitivity analysis using less conservative cut-offs for chronic kidney disease (eGFR <60 ml/min/1.73 m²),²² and iron deficiency (ferritin <30 ng/ml),¹⁸ 289/517 participants had at least one of these three common causes.

† P -value for the significance of the difference of prevalence of anaemia in each thyroid function group compared to the euthyroid state (reference group).

Table 2. Distribution of mean corpuscular volume (MCV) within the different thyroid function groups in the participants with anaemia after the exclusion of three most common causes of anaemia ($n = 396$)^{*}

Thyroid function group	MCV <80 fl $n = 10$ (2.5%)	MCV 80–100 fl $n = 376$ (95.0%)	MCV >100 fl $n = 10$ (2.5%)
Overt and subclinical hypothyroidism	0 (0.0)	34 (9.4)	2 (5.6) [†]
Euthyroidism	10 (2.9)	329 (95.1)	7 (2.0)
Overt and subclinical hyperthyroidism	0 (0.0)	13 (92.9)	1 (7.1) [†]

Fisher's exact test[‡] = 0.28

^{*}defined as ferritin <15 ng/ml, CRP \geq 10 mg/l and/or estimated glomerular filtration rate (eGFR) \leq 30 ml/min/1.73 m².

[†]One participant with subclinical hypothyroidism, one participant with overt hypothyroidism and one participant with subclinical hyperthyroidism.

[‡]Fisher's exact test for difference in MCV category (<80 fl, 80–100 fl, >100 fl) across the three different thyroid function groups (overt and subclinical hypothyroidism; euthyroidism; overt and subclinical hyperthyroidism).




Fig. 1 Comparison of haemoglobin (Hb) levels with 95% confidence intervals (CI) across thyroid function groups, adjusted for age and sex. Quadratic pattern linear analysis showed that participants in the euthyroid state had the highest levels of Hb, and that Hb values were lower in the participants with both hyper- or hypothyroid dysfunction, with a greater difference in the participants with overt than subclinical thyroid dysfunction (P -value for quadratic pattern <0.001). The only group which significantly differed from the euthyroid reference group was OHyper (Hb -0.49 g/dl; CI -0.93 to -0.05 ; $P = 0.03$), while the difference was borderline significant for OHypo (Hb -0.17 g/dl; CI -0.33 to 0.00 ; $P = 0.05$). OHypo: overt hypothyroidism; SHypo: subclinical hypothyroidism; SHyper: subclinical hyperthyroidism; OHyper: overt hyperthyroidism.

In this large population-based cohort, the prevalence of anaemia was higher among adults with overt hyperthyroidism, borderline significantly higher in those with overt hypothy-

roidism, while it did not differ in those with subclinical thyroid dysfunction, compared to the euthyroid state. Although most guidelines recommend a systematic TSH measurement among patients with anaemia,^{2,11–14} screening for thyroid dysfunction leads to the identification of only 4.8% (19/396) of adults with overt thyroid dysfunction after excluding three other common causes of anaemia. This proportion might have been even further reduced by excluding participants with anaemia due to vitamin B12 and/or folate deficiency, which were not assessed in the EPIC-Norfolk cohort and account for about 14% of causes of mainly macrocytic anaemia in other population-based studies.²⁰ A previous small study ($n = 400$) in ambulatory care found that the prevalence of anaemia, after excluding other common etiologies, was significantly higher in patients with overt (43%, $P = 0.0003$) or subclinical (39%, $P = 0.021$) hypothyroidism when compared with healthy controls (23%).⁶ Our results suggest a higher prevalence of anaemia in participants with overt, but not in those with subclinical hypothyroidism. This partial discrepancy could be explained by the high prevalence of anaemia (33% compared to ours at 5.9%), possibly due to different population characteristics and study design; this previous study was indeed not population-based and included 60–70% participants with anaemia of chronic disease.⁶

We found a high prevalence of anaemia in participants with hyperthyroidism (14.6%). Data on this association are very scarce, mainly consisting of case reports.^{7,8} Several mechanisms have been proposed for this association, such as anti-thyroid drugs toxicity leading to aplasia, auto-immune haemolysis, impairment in the utilization of iron or increased oxidative stress leading to increased erythrocyte osmotic fragility and haemolysis.^{7–10} Further studies should confirm this finding.

The small prevalence of macrocytosis in our study is consistent with previous studies^{10–13} and further supports the fact that macrocytosis, although traditionally associated with hypothyroidism, is probably a rare finding in this population and rather relates to severe hypothyroidism.^{11–14} However, studies with larger number of participants with macrocytosis are warranted to confirm our findings.

Our study has some limitations. TSH was measured only once at baseline, which is a limitation of most previous cohorts on the risks associated with thyroid dysfunction,^{27–29} and we might have found a stronger relationship between subclinical thyroid dysfunction and anaemia if we had studied only participants with persistent subclinical thyroid dysfunction. We did not measure vitamin B12 and folate; however, daily folate and vitamin B12 intakes were 200–350 μ g³⁰ and 2–14 μ g,³¹ respectively, in the EPIC-Norfolk cohort, which fulfils the current nutritional recommendations for both vitamins.^{31,32}

In conclusion, our data from the largest population-based study on this issue suggest that the prevalence of anaemia is higher in overt hyperthyroidism and borderline statistically significant higher in overt hypothyroidism, but not increased in subclinical thyroid dysfunction. TSH measurement should not be routinely recommended in the initial work-up of anaemia, but only after excluding other common causes, such as iron deficiency, chronic kidney disease, inflammatory disease and

vitamin B12 and folate deficiency. Furthermore, if measured in the etiologic work-up of anaemia, TSH should not be restricted to the macrocytic cases.

Acknowledgements

This project was supported by a grant from the Swiss National Science Foundation (SNSF 320030–150025) and partially by a grant from the Swiss Heart Foundation (both to Prof Rodondi). Dr Collet's research is supported by grants from the Swiss National Science Foundation (PBLAP3-145870, P3SMP3-155318). We thank the EPIC-Norfolk cohort for permission to access the data.

Conflict of interests

Nothing to declare.

Author contributions

Prof Rodondi had full access to all of the data in the study, takes responsibility for the integrity of the data and the accuracy of the data analysis and is the guarantor. Study concept and design: Rodondi. Acquisition of data: Luben and Khaw. Analysis and interpretation of data: M'Rabet-Bensalah, Aubert, Coslovsky and Rodondi. Drafting of the manuscript: M'Rabet-Bensalah, Aubert, Rodondi. Critical revision of the manuscript for important intellectual content: den Elzen, Aujesky, Luben, Khaw, Coslovsky, Collet, Baumgartner, Angelillo-Scherrer. Statistical analysis: Coslovsky. Study supervision: Rodondi.

References

- Vitale, G., Fatti, L.M., Prolo, S. *et al.* (2010) Screening for hypothyroidism in older hospitalized patients with anemia: a new insight into an old disease. *Journal of the American Geriatrics Society*, **58**, 1825–1827.
- Lee, G.R., Foerster, J., Lukens, J. *et al.* (1999) Anemia: a diagnostic strategy. In: J.P. Greer, J. Forester, G.M. Rogers, *et al.* eds. *Wintrobe's Clinical Hematology*, 10th edn. Williams & Wilkins, Baltimore, Philadelphia, 908–940.
- Patel, K.V. (2008) Epidemiology of anemia in older adults. *Seminars in Hematology*, **45**, 210–217.
- Surks, M.I., Ortiz, E., Daniels, G.H. *et al.* (2004) Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. *JAMA*, **291**, 228–238.
- Hollowell, J.G., Staehling, N.W., Flanders, W.D. *et al.* (2002) Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *Journal of Clinical Endocrinology and Metabolism*, **87**, 489–499.
- Erdogan, M., Kösenli, A., Ganidagli, S. *et al.* (2012) Characteristics of anemia in subclinical and overt hypothyroid patients. *Endocrine Journal*, **59**, 213–220.
- Thomas, D., Moisisidis, A., Tsiakalos, A. *et al.* (2008) Antithyroid drug-induced aplastic anemia. *Thyroid*, **18**, 1043–1048.
- Ogihara, T., Katoh, H., Yoshitake, H. *et al.* (1987) Hyperthyroidism associated with autoimmune hemolytic anemia and periodic paralysis: a report of a case in which antihyperthyroid therapy alone was effective against hemolysis. *Japanese Journal of Medicine*, **26**, 401–403.
- Yücel, R., Ozdmeir, S., Daryerli, N. *et al.* (2009) Erythrocyte osmotic fragility and lipid peroxidation in experimental hyperthyroidism. *Endocrine*, **36**, 498–502.
- Rivlin, R.S. & Wagner, H.N. Jr (1969) Anemia in hyperthyroidism. *Annals of Internal Medicine*, **70**, 507–516.
- Colon-Otero, G., Menke, D. & Hook, C.C. (1992) A practical approach to the differential diagnosis and evaluation of the adult patient with macrocytic anemia. *Medical Clinics of North America*, **76**, 581–597.
- Hoffbrand, V. & Provan, D. (2007) Macrocytic Anaemias. In: D. Provan ed. *ABC of Clinical Haematology*, 3rd edn. Blackwell Publishing, London, 6–10.
- Barton, G., Caswell, M., Ellison, P. *et al.* (2013) Macrocytic anaemia. In: M. Tilyard, R. Harris eds. *Best Tests: Investigating Anemia*. Bpac, Dunedin, 15–19.
- Kaferle, J. & Strzoda, C.E. (2009) Evaluation of macrocytosis. *American Family Physician*, **79**, 203–208.
- Horton, L., Coburn, R.J., England, J.M. *et al.* (1976) The haematology of hypothyroidism. *The Quarterly Journal of Medicine*, **45**, 101–123.
- Christ-Crain, M., Meier, C., Huber, P. *et al.* (2003) Effects of restoration or euthyroidism on peripheral blood cells and erythropoietin in women with subclinical hypothyroidism. *Hormones*, **2**, 237–242.
- Fein, H.G. & Rivlin, R.S. (1975) Anemia in thyroid diseases. *Medical Clinics of North America*, **59**, 1133–1145.
- Myint, P.K., Luben, R.N., Wareham, N.J. *et al.* (2009) Combined effect of health behaviours and risk of first ever stroke in 20,040 men and women over 11 years' follow-up in Norfolk cohort of European Prospective Investigation of Cancer (EPIC Norfolk): prospective population study. *BMJ*, **33**, 8–349.
- World Health Organization (2011) Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. VMNIS | Vitamin and Mineral Nutrition Information System (WHO/NMH/NHD/MNM/11.1; <http://www.who.int/vmnis/indicators/haemoglobin.pdf>) (accessed 11 July 2015).
- Guralnik, J.M., Eisenstaedt, R.S., Ferrucci, L. *et al.* (2004) Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. *Blood*, **104**, 2263–2268.
- Den Elzen, W.P.J., De Craen, A.J.M., Wiegerinck, E.T. *et al.* (2013) Plasma hepcidin levels and anemia in old age. The Leiden 85-Plus Study. *Haematologica*, **98**, 448–454.
- World Health Organisation (2001) Iron Deficiency Anaemia. Assessment, Prevention, and Control. A guide for programme managers. SHO/NHD/01.3 (http://www.who.int/nutrition/publications/en/ida_assessment_prevention_control.pdf) (accessed 7 August 2015).
- Astor, B.C., Muntner, P., Levin, A. *et al.* (2002) Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988–1994). *Archives of Internal Medicine*, **162**, 1401–1408.
- National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *American Journal of Kidney Diseases*, **39**(2 Suppl 1), S1–S266.
- Akbari, A., Clase, C.M., Acott, P. *et al.* (2015) Canadian Society of Nephrology commentary on the KDIGO clinical practice

- guideline for CKD evaluation and management. *American Journal of Kidney Diseases*, **65**, 177–205.
- 26 Kidney Disease Improving Global Outcomes (KDIGO) (2012) KDIGO Clinical practice guidelines for anemia in chronic kidney disease. Official Journal of the International Society of Nephrology. *Kidney International Supplements* (http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-Anemia%20GL.pdf), 2: 288–291 (accessed 7 August 2015).
- 27 Chaker, L., Heeringa, J., Dehghan, A. *et al.* (2015) Normal thyroid function and the risk of atrial fibrillation: the Rotterdam Study. *Journal of Clinical Endocrinology and Metabolism*, **100**, 3718–3724.
- 28 Rodondi, N., Newman, A.B., Vittinghoff, E. *et al.* (2005) Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. *Archives of Internal Medicine*, **165**, 2460–2466.
- 29 Walsh, J.P., Bremner, A.P., Bulsara, M.K. *et al.* (2005) Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. *Archives of Internal Medicine*, **165**, 2467–2472.
- 30 Park, J., Nicolas, G., Freisling, H. *et al.* (2012) Comparison of standardised dietary folate intake across ten countries participating in the European Prospective Investigation into Cancer and Nutrition. *The British Journal of Nutrition*, **108**, 552–569.
- 31 Olsen, A.A., Halkjaer, J., van Gils, C.H. *et al.* (2009) Dietary intake of the water-soluble vitamins B1, B2, B6, B12 and C in 10 countries in the European Prospective Investigation into Cancer and Nutrition. *European Journal of Clinical Nutrition*, **63**(Suppl 4), S122–S149.
- 32 De Bree, A., van Dusseldorp, M., Brouwer, I.A. *et al.* (1997) Folate intake in Europe: recommended, actual and desired intake. *European Journal of Clinical Nutrition*, **51**, 643–660.